• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.

    11/13/25 12:43:57 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Inventiva S.A.

    (Name of Issuer)


    Ordinary shares, par value $0.01 per share

    (Title of Class of Securities)


    46124U107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    46124U107


    1Names of Reporting Persons

    Yiheng Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,597,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,597,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,597,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.46 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    46124U107


    1Names of Reporting Persons

    Yiheng Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,597,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,597,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,597,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.46 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    46124U107


    1Names of Reporting Persons

    Yiheng Capital Management, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,597,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,597,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,597,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.46 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    46124U107


    1Names of Reporting Persons

    Yuanshan Guo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,597,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,597,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,597,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.46 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inventiva S.A.
    (b)Address of issuer's principal executive offices:

    50 Rue De Dijon, Daix, France 21121
    Item 2. 
    (a)Name of person filing:

    This Statement is being filed by Yiheng Capital Management, LP, a Delaware limited partnership (the "Investment Manager"), Yiheng Capital Partners, L.P., a Delaware limited partnership (the "Partnership"), and Yuanshan Guo, the managing member of the Investment Manager ("Mr. Guo" and, together with the Investment Manager and Partnership, the "Reporting Persons"). The Reporting Persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of such securities. This Statement relates to the Ordinary shares, par value $0.01 per share held for the account of the Partnership. The Investment Manager serves as investment manager to the Partnership. Mr. Guo is the managing member of the Investment Manager. In such capacity, Mr. Guo and the Investment Manager may be deemed to have voting and dispositive power with respect to the Ordinary shares, par value $0.01 per share held for the Partnership.
    (b)Address or principal business office or, if none, residence:

    The principal office of each Reporting Person is 101 California Street, Suite 2880, San Francisco, CA 94111.
    (c)Citizenship:

    The Investment Manager is a Delaware limited partnership. The Partnership is a Delaware limited partnership. Mr. Guo is a citizen of the United States of America.
    (d)Title of class of securities:

    Ordinary shares, par value $0.01 per share
    (e)CUSIP No.:

    46124U107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    7,597,148
    (b)Percent of class:

    5.46  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    7,597,148

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    7,597,148

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Yiheng Capital Partners, L.P.
     
    Signature:/s/ Yuanshan Guo
    Name/Title:Yuanshan Guo / Managing Member
    Date:11/13/2025
     
    Yiheng Capital, LLC
     
    Signature:/s/ Yuanshan Guo
    Name/Title:Yuanshan Guo / Managing Member
    Date:11/13/2025
     
    Yiheng Capital Management, LP
     
    Signature:/s/ Yuanshan Guo
    Name/Title:Yuanshan Guo / Managing Member
    Date:11/13/2025
     
    Yuanshan Guo
     
    Signature:/s/ Yuanshan Guo
    Name/Title:Yuanshan Guo / Managing Member
    Date:11/13/2025
    Get the next $IVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    11/6/2025$13.00Outperform
    Wolfe Research
    9/3/2025$20.00Buy
    H.C. Wainwright
    8/27/2025$26.00Overweight
    Piper Sandler
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    More analyst ratings

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Inventiva with a new price target

    Wolfe Research initiated coverage of Inventiva with a rating of Outperform and set a new price target of $13.00

    11/6/25 8:48:14 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Inventiva with a new price target

    H.C. Wainwright resumed coverage of Inventiva with a rating of Buy and set a new price target of $20.00

    9/3/25 8:38:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Inventiva with a new price target

    Piper Sandler initiated coverage of Inventiva with a rating of Overweight and set a new price target of $26.00

    8/27/25 8:23:53 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inventiva announces trading resumption of its ordinary shares on Euronext Paris

    Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET).  Trading of the ordinary shares of the Company was halted, at the Company's request, on November 13, 2025, from 9:00 a.m. (CET), in the context of the previously announced public offering by the Company in the United States only of new American Deposita

    11/13/25 10:24:53 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares

    Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01, at an offering price of $3.85 per ADS (the "Offering"). Settlement and delivery of the Offering is expected on November 17, 20

    11/13/25 9:21:56 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

    Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. (CET). This trading halt takes place in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares

    11/13/25 2:40:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    SEC Filings

    View All

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    11/13/25 4:56:38 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Inventiva S.A.

    424B5 - Inventiva S.A. (0001756594) (Filer)

    11/13/25 4:40:16 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.

    SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)

    11/13/25 12:43:57 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    View All

    Inventiva Appoints Andrew Obenshain as Chief Executive Officer

    Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Andrew Obenshain as Chief Executive Officer ("CEO") of the Company. Mr. Obenshain will also join the Company's Board of Directors. He succeeds Frédéric Cren, the Company's co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth tr

    10/1/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

    Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic

    7/9/25 4:05:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

    Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

    6/10/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 9:00:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 8:54:43 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Financials

    Live finance-specific insights

    View All

    Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

    Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

    5/5/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    3/26/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    3/19/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care